舒格利單抗攻城掠地再下一城,基石藥業與Pharmalink達成商業化戰略合作
基石藥業(2616.HK)今日宣佈與Pharmalink Store- L.L.C - O.P.C(“Pharmalink”)達成商業化戰略合作,該合作是基石藥業就舒格利單抗全球商業化達成的第二項重大國際合作。繼2024年上半年與Ewopharma在中歐/東歐地區及瑞士達成的戰略合作之後,此次合作進一步向中東和非洲地區拓展了舒格利單抗的全球佈局。基石藥業預計近期將在西歐、拉丁美洲、東南亞及加拿大等地區達成更多商業合作。Pharmalink是一家總部設在阿拉伯聯合酋長國的知名醫藥公司。根據許可及商業化協議,Pharmalink將獲得舒格利單抗在中東和北非地區,包括沙特阿拉伯、阿拉伯聯合酋長國、科威特、卡塔爾、阿曼、巴林,阿爾及利亞、突尼斯、埃及、摩洛哥、利比亞,以及南非的商業化權利。基石藥業首席執行官、研發總裁及執行董事楊建新博士表示,舒格利單抗是首個成功登陸全球第二大醫藥市場——歐盟,及英國的由中國生物製藥企業研發的PD-L1單抗。我們也在積極推進與監管機構就舒格利單抗包括III期非小細胞肺癌、一線胃癌、一線食管鱗癌在內其他適應症註冊上市的討論。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.